How Q3 Results Will Impact Liquidia (LQDA) Investors

Simply Wall St.11-14 14:18

Liquidia reported Q3 2026 results on November 10, 2026, with revenue of US$225.3 million and a net loss of US$236.33 million, or a basic loss of US$2.64 per share from continuing operations. The nine ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2683680392?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-11-14 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683680392","market":"sg","top_or_hot":-1,"title":"How Q3 Results Will Impact Liquidia (LQDA) Investors","media":"Simply Wall St.","content":"<div>\n<p>Liquidia reported Q3 2026 results on November 10, 2026, with revenue of US$225.3 million and a net loss of US$236.33 million, or a basic loss of US$2.64 per share from continuing operations. The nine ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/how-q3-results-will-impact-liquidia-lqda-investors\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Q3 Results Will Impact Liquidia (LQDA) Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Q3 Results Will Impact Liquidia (LQDA) Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-14 14:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/how-q3-results-will-impact-liquidia-lqda-investors><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Liquidia reported Q3 2026 results on November 10, 2026, with revenue of US$225.3 million and a net loss of US$236.33 million, or a basic loss of US$2.64 per share from continuing operations. The nine ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/how-q3-results-will-impact-liquidia-lqda-investors\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/how-q3-results-will-impact-liquidia-lqda-investors","article_id":"2683680392","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/how-q3-results-will-impact-liquidia-lqda-investors","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683680392","pubTimestamp":1794637096,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"MMitch LawlerNovember 14, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","PMDE":"PGIM S&P 500 Max Buffer ETF - December","LQDA":"Liquidia Technologies Inc","RGLO":"Global Equity Active ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","ISBC":"投资者银行","VOTE":"TCW Transform 500 ETF","VGFPF":"Vanguard Funds PLC","GXDW":"Global X Dorsey Wright Thematic ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","BK4007":"制药"},"translate_title":"第三季度业绩将如何影响 Liquidia (LQDA) 投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VGFPF":0.69,"LQDA":1.5,"RGLO":0.69,"FEBU":0.69,"JOYT":0.69,"GXDW":0.69,"DECU":0.69,"VOTE":0.69,"ISBC":1.5,"PMDE":0.69},"content_text":"Liquidia reported Q3 2026 results on November 10, 2026, with revenue of US$225.3 million and a net loss of US$236.33 million, or a basic loss of US$2.64 per share from continuing operations. The nine month figures show US$529.84 million in revenue alongside a US$108.74 million net loss, underscoring how Liquidia’s current commercial and development spending is weighing on profitability even as reported sales increase. This article reviews how Liquidia’s sharp Q3 revenue and loss profile influences the investment narrative around pulmonary hypertension therapies.  Scan Liquidia’s results in context by comparing its pulmonary hypertension story with 36 healthcare AI stocks that are also pouring cash into high-risk, high-reward treatment platforms. AdvertisementLiquidia Investment Narrative Recap To own Liquidia, you need to believe its pulmonary hypertension franchise can justify heavy spending and current losses. The analyst consensus Narrative on Simply Wall St leans on YUTREPIA prescription momentum, improving payer access and the potential for L606 to eventually share the same commercial and manufacturing backbone. The latest quarter, with high reported revenue but an even larger loss, highlights how dependent that belief is on execution. The sharp Q3 loss keeps the near term focus on two things. First, whether YUTREPIA vouchers and bridge programs convert into sustained, reimbursed use that supports cleaner revenue and cash generation. Second, whether investment in North Carolina capacity and the broader pipeline stretches the balance sheet before demand and L606 can help support it. The Q3 2026 earnings announcement is the key reference point right now. Management reported US$225.3 million of revenue alongside a net loss of US$236.33 million for the quarter, and a US$108.74 million loss over nine months on US$529.84 million of sales. That mix of scale and red ink brings the risk section of the analyst consensus Narrative on Simply Wall St into sharper focus for Liquidia. You are essentially watching three operational levers at once: payer terms and gross to net for YUTREPIA, the decision to build out manufacturing that could triple capacity, and the clinical and regulatory path for L606. If YUTREPIA pricing pressure persists or long term demand does not fill that extra capacity, the current loss profile could weigh on the story for longer. Liquidia's narrative projects US$942.5 million revenue and US$368.9 million earnings by 2029. This assumes 14.9% yearly revenue growth and an earnings increase of roughly US$463.1 million from current earnings of a US$94.2 million loss. Uncover why Liquidia's fair value indicates that Liquidia is roughly in line with its current price. NasdaqCM:LQDA 1-Year Stock Price Chart Exploring Other Perspectives One sharp contrast in the alternate Liquidia story is the concern that higher R&D and the US$380.7 million settlement could squeeze future earnings. The most cautious analysts were only penciling in about US$861.0 million of 2029 revenue and US$327.6 million of earnings before this Q3 release, which paints a much tougher road. That gap in expectations shows how far views can spread, so use this earnings update as a prompt to explore several investor narratives before deciding where you sit. Explore 4 other Liquidia fair value estimates, including one that suggests as much as 37% downside from the current price! The Verdict Is Yours Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.  A great starting point for your Liquidia research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. See our latest analysis for Liquidia. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Liquidia's overall financial health at a glance.  Looking for more Liquidia-sized investment ideas? If Liquidia has sharpened your appetite for deeper research, broaden your watchlist with companies filtered by the traits you care about most using the Simply Wall St Screener.  If capital preservation ranks high for you, scan a focused group of 31 resilient stocks with low risk scores to see which businesses score well on stability and risk controls. If balance sheet strength is your starting filter, move through a curated list of solid balance sheet and fundamentals (24 results) to find companies where debt levels and cash buffers look more robust. If you are hunting for potential under the radar opportunities, sift through a 20 high quality undiscovered gems that combines quality fundamentals with relatively low market attention.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2683680392","isCrawlerRequest":true}